Nabil F. Saba
Experienced in Glossectomy

Dr. Nabil F. Saba

Oncology | Hematology | Hematology Oncology
550 Peachtree St NE, Fl 10, Ste 1090, 
Atlanta, GA 
 (284.5 mi)
Offers Telehealth
Experienced in Glossectomy
550 Peachtree St NE, Fl 10, Ste 1090, 
Atlanta, GA 
 (284.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Nabil Saba is an Oncologist and a Hematologist in Atlanta, GA. Dr. Saba and is rated as an Experienced provider by MediFind in Glossectomy. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Glossectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Glossectomy.

Residency
Tufts University School of Medicine
Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Emory University Hospital Midtown
Emory Johns Creek Hospital
Emory University Hospital
Emory Decatur Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Arabic
French
Gender
Male
Awards
Atlanta Magazine's "Top Doctors", 2005, 2016-2020
MilliPub Club Award, Emory University School of Medicine, 2020
Director's Service Award, National Cancer Institute, 2019
Outstanding reviewer for journal, Cancer, 2017
Castle Connolly Top Doctors, 2011 and 2014
Distinguished Doctor, Expert Network, 2015

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Oscar
  •  Humana

Locations

Winship at Emory University Hospital Midtown
550 Peachtree St NE, Fl 10, Ste 1090, Atlanta, GA 30308

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Cabozantinib, Pembrolizumab
Study Phase: Phase 2
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological, Radiation
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: FS118
Study Phase: Phase 1/Phase 2
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: CUE-101, Pembrolizumab
Study Phase: Phase 1
View 6 Less Clinical Trials

235 Total Publications

Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Journal: Nature medicine
Published: July 02, 2024

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile